HRT duration/counseling — FDA black box removal + surgical menopause risks
Key Questions
What changes did the FDA make to menopause hormone therapy labels in 2026?
The FDA removed three long-standing black-box warnings from menopause hormone therapy labels in March 2026. This reflects updated safety data after two decades.
How does norethindrone compare to progesterone for menopausal women?
Norethindrone and progesterone differ in their effects and are chosen based on individual patient profiles. Clinicians weigh these options carefully during menopause management.
Does HRT improve outcomes with tirzepatide for weight loss?
Mayo Clinic data show HRT combined with tirzepatide increases weight loss by 35% in postmenopausal women. This supports integrated approaches to menopausal weight management.
Is there a dementia link with HRT use?
A Lancet meta-analysis confirms no association between HRT and dementia risk. This finding helps inform counseling after black-box label updates.
What risks arise from ovarian-sparing hysterectomy?
New PROOF study and 2026 Canadian cohort data show accelerated ovarian aging, earlier menopause, and higher CV/bone risks after ovarian-sparing hysterectomy. These challenge prior assumptions of hormonal neutrality.
FDA stripped three black-box warnings from menopause hormone therapy labels (March 2026). Norethindrone vs. progesterone comparison. Mayo Clinic study: HRT boosts tirzepatide weight loss by 35%. Lancet meta-analysis confirms no dementia link with HRT. New this run: New evidence challenges ovarian-sparing hysterectomy as hormonally neutral — PROOF study and 2026 Canadian cohort show accelerated ovarian aging, earlier menopause, increased CV/bone risks. Also: estrogen patch shortage due to demand surge from black box removal. WHI 2024 follow-up on HRT timing.